Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Survodutide
BI 456906, Boehringer Ingelheim dual agonist
Retatrutide
LY3437943, Eli Lilly Triple Agonist
A dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim for obesity and metabolic liver disease (MASH/NASH). Unlike tirzepatide (GIP/GLP-1), survodutide activates the glucagon receptor alongside GLP-1, which increases energy expenditure and hepatic fat oxidation. Phase 2 trials showed up to 18.7% weight loss at 46 weeks and significant liver fat reduction, making it a leading candidate for MASH treatment.
An investigational triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials are underway, with early results showing unprecedented weight loss efficacy.
Dual agonism of glucagon and GLP-1 receptors. GLP-1 activation reduces appetite and slows gastric emptying. Glucagon activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The combination targets both caloric intake and energy output, with particular benefit for liver fat reduction — a mechanism not shared by pure GLP-1 agonists.
Activates three metabolic hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin response, fat metabolism), and glucagon (increased energy expenditure, fat oxidation). The triple mechanism may produce greater weight loss than dual agonists.
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Metabolic syndrome
- Liver fat reduction
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome (investigational)
- GI side effects (nausea, vomiting, diarrhea) — common in GLP-1 class
- Potential blood sugar effects from glucagon activation
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- Still in clinical trials — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting) reported in trials
- Not yet approved for any indication
- Long-term effects unknown
Currently in Phase 3 trials for obesity (SYNCHRONIZE program) and MASH (LIVERAGE program). Phase 2 data showed 18.7% weight loss at 46 weeks and 87% relative reduction in liver fat. Potential FDA submission expected 2027. Represents a differentiated mechanism from tirzepatide and semaglutide.
Currently in Phase 3 clinical trials. Phase 2 results showed up to 24% body weight loss at 48 weeks. FDA approval timeline uncertain but potentially 2027-2028.
- Survodutide for MASH: Phase 2 results (LIVERAGE)
2024 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.